drugset / Trial / NCT04893252
Vactosertib and Durvalumab in Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Vactosertib | Small molecule | — | Oral |